AXSM Maintained: Guggenheim, Piper Sandler Raise Targets May 2026

Axsome Therapeutics (AXSM) held steady as four major analysts raised their price targets on May 4, 2026. Guggenheim, Piper Sandler, Cantor Fitzgerald, and Jefferies all maintained their positive analyst maintained rating while boosting price forecasts. The biotech firm, valued at $11.4 billion, trades in the healthcare sector developing CNS disorder treatments. Stock price movement reflected mixed sentiment despite the analyst maintained rating upgrades. We examine what these target increases mean for investors tracking this pharmaceutical developer.

Four Analysts Raise Price Targets on Analyst Maintained Rating

Guggenheim Lifts Target to $260

Guggenheim raised its price target to $260 from $245, maintaining a Buy rating on AXSM. The analyst maintained rating reflects confidence in the company’s pipeline progress. Guggenheim’s price target increase signals optimism about near-term catalysts. The $15 boost represents a 6.1% upside from the previous target.

Piper Sandler Increases Target to $258

Piper Sandler raised its price target to $258 from $223, maintaining an Overweight rating. This $35 increase marks a 15.7% jump from the prior target. The analyst maintained rating shows continued confidence in AXSM’s commercial execution. Piper’s target suggests meaningful upside potential for shareholders.

Cantor Fitzgerald Sets Highest Target at $272

Cantor Fitzgerald raised its price target to $272 from $234, maintaining an Overweight rating. The $38 increase represents a 16.2% boost from the previous target. Cantor’s analyst maintained rating reflects strong conviction in the company’s growth trajectory. This highest target among the four analysts indicates robust confidence in AXSM’s prospects.

Jefferies Raises Target to $275

Jefferies raised its price target to $275 from $245, maintaining a Buy rating. The $30 increase represents a 12.2% jump from the prior target. Jefferies’ analyst maintained rating aligns with the broader bullish sentiment. The firm’s target is the highest among all four analysts reviewed today.

Meyka AI Stock Grade and Market Position

Meyka Rates AXSM with Grade B

Meyka AI rates AXSM with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B grade reflects solid fundamentals despite current profitability challenges. These grades are not guaranteed and we are not financial advisors.

Market Cap and Trading Metrics

Axsome Therapeutics trades with an $11.4 billion market cap on NASDAQ. The stock closed at $223.34, up 8.14% on the day with strong volume of 2.5 million shares. The 50-day average price stands at $171.71, while the 200-day average is $147.56. Year-to-date performance shows a 22.3% gain, reflecting investor optimism about pipeline progress.

Pipeline Progress Drives Analyst Maintained Rating Confidence

CNS Drug Development Pipeline

Axsome develops novel therapies for central nervous system disorders. AXS-05 treats major depressive disorder and resistant depression, with Phase III trials underway for Alzheimer’s disease agitation. AXS-07 completed two Phase III trials for acute migraine treatment. AXS-12 targets narcolepsy in Phase III trials, while AXS-14 addresses fibromyalgia. The diverse pipeline supports the analyst maintained rating across multiple firms.

Analyst Consensus and Rating Distribution

The analyst maintained rating consensus shows 33 Buy ratings and just 1 Sell rating among tracked analysts. No Hold ratings appear in the consensus data. This overwhelmingly bullish stance supports the price target increases announced today. The consensus rating of 3.0 reflects strong institutional confidence in AXSM’s direction.

Financial Metrics and Valuation Considerations

Current Valuation Metrics

AXSM trades at a price-to-sales ratio of 16.36x, reflecting premium biotech valuation. The company shows negative earnings with an EPS of -$3.68 and PE ratio of -60.81. Price-to-book ratio stands at 117.09x, indicating high market expectations. These metrics reflect typical biotech valuations for pre-profitability companies with strong pipeline potential.

Revenue and Cash Position

Axsome generated $12.61 in revenue per share trailing twelve months. The company maintains $6.38 in cash per share, providing runway for clinical development. Operating cash flow remains negative at -$1.84 per share. The analyst maintained rating acknowledges these financial realities while betting on future commercialization success.

Final Thoughts

Four major analysts raised AXSM price targets on May 4, 2026, averaging $27 increases with Jefferies setting the highest at $275. Their maintained positive ratings reflect confidence in Axsome Therapeutics’ CNS drug pipeline. Meyka AI grades AXSM as B-rated, acknowledging solid fundamentals but noting profitability challenges. The stock trades at a premium 16.36x sales. While the constructive analyst environment supports the outlook, clinical trial results and regulatory decisions remain critical catalysts for future performance.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.